ArticleACS applied bio materials2026
Optimizing the Hemoglobin-Based Oxygen Carrier Molecular Size to Balance Vascular Function and Hemodynamic Responses after Transfusion.
Article in ACS applied bio materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Hemorrhagic shock remains a leading cause of mortality due to impaired oxygen delivery following severe blood loss. Hemoglobin-based oxygen carriers (HBOCs) are promising alternatives to red blood cell transfusion; however, their molecular size critically governs nitric oxide (NO) scavenging, vascular reactivity, and overall safety. Here, we systematically evaluated acellular human hemoglobin (hHb) and four polymerized hemoglobin formulations with progressively increasing molecular weights (PolyhHb-10, ∼1080 kDa; PolyhHb-12, ∼1200 kDa; PolyhHb-15, ∼1490 kDa; and PolyhHb-16, ∼1570 kDa) to define size-dependent determinants of vascular function. Ex vivo, isolated mesenteric arterioles from New Zealand white rabbits were perfused with HBOC-whole blood mixtures (1:0, 1:1, and 1:3) across physiologically relevant flow rates to quantify shear-mediated vasodilation and endothelial function. The acetylcholine challenge was used to probe NO bioavailability. In vivo validation was performed in Golden Syrian hamsters using a dorsal window chamber model to assess microvascular hemodynamics, including the vessel diameter, blood flow, and functional capillary density. PolyhHb-12 consistently preserved endothelial-dependent vasodilation and exhibited minimal NO scavenging across conditions. In contrast, larger polymers (PolyhHb-15 and PolyhHb-16) showed paradoxically increased NO scavenging despite improved capillary perfusion, indicating a trade-off between microcirculatory flow enhancement and endothelial signaling. In vivo, increasing the molecular size yielded diminishing returns in overall hemodynamic stability. Together, these findings identify an intermediate molecular size as optimal for balancing rheological properties, NO bioavailability, and vascular function. PolyhHb-12 emerges as a lead candidate, supporting the design of next-generation HBOCs with improved safety and efficacy for hemorrhagic shock resuscitation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.